Project Grant R21AI185437
Award Date 8/7/25
Completion Date 7/31/27
Dollars Obligated $254K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The federal Project Grant award of $746,602 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Cornell University. The objective of this 5-year project is to examine how compounds that stimulate cyclic AMP (cAMP) production in the tuberculosis (TB) bacterium Mycobacterium tuberculosis (MTB) can inhibit its growth and metabolism, potentially enhancing the efficacy of existing TB treatments...
- This Project Grant award of $2,944,529 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand resistance and tolerance to the tuberculosis (TB) drugs pretomanid (PA) and delamanid (DLM) in Mycobacterium tuberculosis (MTB). The goal is to apply innovative genome-wide screens to identify the MTB genes that determine PA/DLM potency, analyze the key resistance determinant...
- This federal Project Grant award of $819,998.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), to The Regents of the University of California, San Francisco. The purpose of the award is to conduct research to understand how Mycobacterium tuberculosis (M. tuberculosis) infection triggers host cell death mechanisms, with the goal of identifying new therapeutic targets to augment protective...
- This $162,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (PDCs) in Mycobacterium tuberculosis (MTB) infection. The research aims to quantify PDC trafficking and activation in the lungs during MTB infection, and determine how PDC-driven type I interferon responses impact MTB control. The project will leverage a mouse model that...
- This Project Grant award of $461,250 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is funding research at Yale University to develop an in vitro culture system that can be used to screen for small molecule inhibitors of drug-tolerant Mycobacterium tuberculosis (MTB) bacteria. The key objectives are to: 1) identify the subcellular environment and carbon source associated with drug-tolerant MTB, and 2) design in vitro...
- This Project Grant award of $3,145,850.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The award supports research at The Johns Hopkins University to investigate macrophage senescence as a driver of granuloma failure and necrosis in pulmonary tuberculosis (TB) and TB/HIV coinfection. Key objectives include understanding the role of stress-induced senescence in myeloid...
- This federal Project Grant award, totaling $404,108, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to identify the key genetic and signaling pathways that enable Mycobacterium tuberculosis (MTB) to form antibiotic persister cells, which can survive prolonged exposure to lethal antibiotics. The research aims to apply genetic and proteomic approaches to...
- This $209,408 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports a research project to characterize the role of unconventional T cell subsets in the immune response to Mycobacterium tuberculosis (MTB) infection using a non-human primate model. The goal is to gain a better understanding of these niche T cell populations in the lung granulomas during the early stages of MTB...
- This $194,940 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) with a start date of August 12, 2025 and an ultimate completion date of July 31, 2030. The primary goal of this research project is to discover the global human genetic regulators, including genes and genetic variants, that control macrophage antimicrobial responses to Mycobacterium tuberculosis (MTB) infection....
- The University of Washington received a $188,760 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research to investigate the role of the lung inflammatory environment and cellular milieu in controlling Mycobacterium tuberculosis (MTB) infection and preventing tuberculosis (TB) disease. Specifically, the research will test the hypothesis that interferon gamma-activated...